Celeste Bello
YOU?
Author Swipe
View article: Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)
Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL) Open
Background and Significance: Cutaneous T-cell lymphoma (CTCL) is a rare, incurable non-Hodgkin lymphoma characterized by progressive Th2 immune skewing, loss of tumor surveillance, and chronic skin inflammation. Interferon-alpha (IFN-α) ha…
View article: Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations
Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations Open
Introduction The CD20xCD3 bispecific antibodies (BsAbs), epcoritamab (Epco) and glofitamab (Glofi), have emerged as effective therapies for relapsed/refractory (RR) B-cell non-Hodgkin lymphomas (B-NHL), demonstrating high response rates in…
View article: Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas
Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas Open
Introduction CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is approved as second-line treatment for aggressive B-cell lymphoma (aBCL), while CD20xCD3 bispecific antibodies (BsAbs) are approved in the third-line setting. Al…
View article: Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study
Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study Open
Introduction: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive lymphoid malignancies characterized by high relapse and mortality rates. Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended upfro…
View article: The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience
The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience Open
Background: Pirtobrutinib is an oral highly selective noncovalent Bruton tyrosine kinase inhibitor (BTKi) that has shown promising efficacy in heavily treated patients with relapsed/refractory (R/R) B cell lymphomas. We conducted a single-…
View article: Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation Open
There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Cla…
View article: Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis Open
The funders had no role in the study.
View article: B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma Open
Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of large B-cell lymphoma with plasmacytic differentiation. Although limited-stage (LS) PBL has a favorable outcome, extensive-stage (ES) PBL has a poor prognosis, with a median …
View article: Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience
Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience Open
Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated …
View article: A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy
A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy Open
Introduction Secondary CNS lymphoma (SCNSL) remains a treatment challenge in patients (pts) with aggressive lymphoma. Outcome of SCNSL is poor. Pts are often treated with high dose Methotrexate (HD-MTX) based regimens followed by autologou…
View article: Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma Open
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin…
View article: Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study Open
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical p…
View article: NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022 Open
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment opt…
View article: Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies Open
Introduction: Patients (pts) with hematological malignancies (HMs) are at increased risk for severe COVID19 infection and death (Grivas, 2021). Currently, vaccination represents the most effective prevention approach. HM pts have been show…
View article: Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Open
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institu…
View article: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma Open
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiation is standard therapy for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin-induced lung injury and radiation toxicity. Brentuximab vedoti…
View article: Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology Open
This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging wit…
View article: Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma
Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma Open
Background: The aim of this study was to evaluate the outcomes of priming salvage radioimmunotherapy (RIT) with a low dose of external beam radiotherapy (EBRT) in patients with relapsed low grade non-Hodgkin lymphoma (LG-NHL). Methods: Pat…
View article: Hodgkin Lymphoma, Version 2.2015
Hodgkin Lymphoma, Version 2.2015 Open
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagn…
View article: Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Open
Key Points Brentuximab vedotin was active in DLBCL across a range of CD30 expression levels, and objective responses occurred in 44% of patients.